The adrenergic bronchodilator is a beta2-adrenergic bronchodilator.
The treatment composition and regimen includes a pair of compatible receptor antagonists and an adrenergic bronchodilator.
These compositions are formulated for pulmonary administration and contain a bronchodilator, a vasoconstrictor, a corticosteroid, and an optional pharmaceutically acceptable carrier.
As an example of the drug, a bronchodilator may be cited while a glicosidase (for example, β-glucuronidase) may be cited as an example of the enzyme.
The invention relates to a Rac1 inhibitor for use as bronchodilator in a patient in need thereof.
The present invention relates to a novel manufacturing process of pharmaceutically active compound of Formula (I) used as a long-acting anticholinergic bronchodilator.
A pharmaceutical or veterinary composition, comprises a first active agent selected from a non-glucocorticoid steroid or analogues, a ubiquinone, or salts thereof, and a second active agent comprising a bronchodilator.
This invention relates to treating pulmonary diseases such as chronic obstructive pulmonary disease or asthma by administering a phosphodiesterase 4 inhibitor in combination with beta adrenergic bronchodilator.
These compounds are useful as a preventive for threatened abortion/premature birth, a bronchodilator and a pain-relieving and lithagogue agent in ureterolithiasis.
Also provided is a method for treating respiratory diseases associated with inflammation comprising administering an NO- donating steroid with at least one bronchodilator.
Provided are novel substituted benzyl compounds represented by general formula (I), which exhibit excellent bronchodilating effect that relies on potent EP2 agonist activity; or salts thereof.
Provided are novel aniline compounds represented by general formula (I), which exhibit excellent bronchodilating effect that relies on potent EP2 agonist activity; or salts thereof.